Physiomics Regulatory News (PYC)

14 Feb 2008 07:00

Physiomics PLC14 February 2008 Physiomics plc ("Physiomics" or "the Company") 14 February 2008 Appointment of Group Financial Controller and Company Secretary Physiomics plc is pleased to announce the appointment of Mr. Roger John Jones asGroup Financial Controller and Company Secretary. Mr. Jones has for 30 yearsbeen a Fellow of the Association of Chartered Certified Accountants and has helda number of senior financial positions and key roles in biotechnology andpharmaceutical companies including Cambridge Antibody Technology, Onyvax,Archimedes Pharma, Angel Biotechnology and Provensis. Commenting on thisannouncement, Physiomics' Chairman, Dr Paul Harper, said: "I am delighted that Roger has agreed to join the Company in these capacities.He brings a wide range of experience to Physiomics and his considerableexperience in the biotech sector make him an especially valuable addition to theexecutive team. We have already worked together on a number of projects and Iknow first hand what he will be able to contribute to the financial, commercialand strategic management of the business." For further information: Physiomics plc +44 (0)7747 842 446Dr Paul HarperE-mail: drpaulharper@tiscali.co.uk Grant Thornton Corporate Finance +44 (0)20 7383 5100Philip Secrett, Colin Aaronson About Physiomics plc Physiomics plc (AIM:PYC) is a computational systems biology services companyapplying simulations of cell behaviour to drug development to reduce the highattrition rates of clinical trials. As 80-90 per cent of all clinical drugcandidates fail to reach the market, estimates1 show that an overall ten percent improvement in success rates could reduce the cost of one drug'sdevelopment by as much as $242 million, from the current estimate of around $800million. Physiomics develops computational systems biology models to predict andunderstand cancer drug efficacy from pre-clinical research to clinicaldevelopment. Physiomics has created detailed mathematical models incorporatingmost important molecular events taking place during the human cell cycle andapoptosis processes. Physiomics developed SystemCell(R) technology, amulti-cellular environment software, which enables the simulation of populationof "virtual cells". Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in2004. For further information, please visit www.physiomics-plc.com SystemCell(R) is a registered trademark of Physiomics plc 1Tufts Centre Impact Report 2002 This information is provided by RNS The company news service from the London Stock Exchange